ALK-Abelló Logo

ALK-Abelló

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for ALK-Abelló. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB
2025-08-12 14:45
Earnings Release
English 3.2 KB
2025-07-18 14:01
Regulatory News Service
Danish 174.9 KB
2025-07-18 14:01
Legal Proceedings Report
English 5.2 KB
2025-07-18 14:01
Regulatory News Service
Danish 5.3 KB
2025-07-18 14:01
Regulatory News Service
English 223.5 KB
2025-05-02 13:59
Regulatory News Service
English 6.2 KB
2025-05-02 13:59
Regulatory News Service
Danish 6.4 KB
2025-05-02 13:59
M&A Activity
English 210.1 KB
2025-05-02 13:59
Earnings Release
Danish 174.8 KB
2025-04-23 15:58
Regulatory News Service
Danish 162.4 KB
2025-04-23 15:58
Regulatory News Service
English 131.9 KB
2025-04-23 15:58
Regulatory News Service
Danish 4.4 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Vivesto Logo
Develops therapies for hard-to-treat cancers in human and veterinary oncology.
Sweden VIVE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo Japan 4512
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden XBRANE
Xspray Pharma Logo
Develops improved PKI cancer drugs using patented amorphous tech for earlier market entry.
Sweden XSPRAY
Y.B Urban Renewal - Residential Development LTD Logo Israel CSURE-M
YUKI GOSEI KOGYO CO.,LTD. Logo Japan 4531
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway ULTI
Zentiva 2 Logo
Develops and commercializes affordable generic, OTC, and biosimilar medicines for patients.
Slovakia SKF
Zentiva S.A. Logo
Develops and distributes affordable generic, OTC, and specialty medicines across Europe.
Romania SCD
ZERIA PHARMCEUTICAL CO., LTD. Logo Japan 4559